Toronto-based AI therapeutics startup, Deep Genomics, has closed a $40 million Series B. This brings the company’s total funding to-date to $61 million. The round was led by Future Ventures and received investments from Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures. The financing will be put toward the development of treatments for rare genetic diseases, in addition to the expansion of Deep Genomics’ AI-based drug discovery platform. Last year, Deep Genomics made the first treatment and drug candidate discovery using AI. Brendan Frey, founder and CEO of Deep Genomics, added that the capital will also allow the … Continue reading Deep Genomics raises $40 million Series B for AI drug discovery platform